Human PTK6 Stable Cell Line - Ba/F3

Protein tyrosine kinase 6, commonly referred to as PTK6 or BRK (breast tumor kinase), is a cytoplasmic non-receptor tyrosine kinase encoded by the PTK6 gene located on human chromosome 20q13.33. Unlike Src-family kinases, PTK6 lacks a myristylation signal and is primarily expressed in the epithelium of the gastrointestinal tract, skin, and oral cavity, though it is also detected at low levels in certain breast tumors while remaining absent in normal mammary tissue. Structurally, PTK6 contains SH3, SH2, and catalytic kinase domains, and it functions as an intracellular signal transducer involved in cell proliferation, migration, differentiation, and survival. The Human PTK6 Stable Cell Line - Ba/F3 is generated by stably transfecting the murine interleukin-3-dependent pro-B cell line Ba/F3 with a constitutively active or full-length human PTK6 expression construct. Because Ba/F3 cells are strictly dependent on IL-3 for growth, successfully generated stable clones acquire cytokine-independent proliferation upon functional expression of an active kinase, making this system a powerful and widely adopted platform for evaluating kinase activity, signaling mechanisms, and pharmacological inhibition.

The Human PTK6 Stable Cell Line - Ba/F3 serves as a valuable in vitro tool for a broad range of research applications. It is particularly well-suited for screening and characterizing small-molecule PTK6 inhibitors, enabling researchers to assess compound potency, selectivity, and cellular efficacy through standard proliferation or viability assays. The cell line also supports mechanistic studies of PTK6-driven signaling pathways, including downstream activation of STAT3, ERK, and AKT, as well as crosstalk with growth factor receptors such as EGFR and ErbB2. Additionally, this stable line can be employed in resistance mechanism studies, combination therapy screening, and target validation efforts in the context of solid tumors where PTK6 overexpression is implicated, such as breast, ovarian, prostate, and colorectal cancers. Its stable and reproducible expression of human PTK6 makes it a reliable model for both academic research and preclinical drug development programs focused on this emerging oncogenic kinase.